DK2970487T3 - Cytotoksiske proteiner omfattende celle-målrettede bindingsregioner og Shiga toksin A-underenhedsregioner til selektivt at dræbe specifikke celletyper - Google Patents
Cytotoksiske proteiner omfattende celle-målrettede bindingsregioner og Shiga toksin A-underenhedsregioner til selektivt at dræbe specifikke celletyper Download PDFInfo
- Publication number
- DK2970487T3 DK2970487T3 DK14726015.2T DK14726015T DK2970487T3 DK 2970487 T3 DK2970487 T3 DK 2970487T3 DK 14726015 T DK14726015 T DK 14726015T DK 2970487 T3 DK2970487 T3 DK 2970487T3
- Authority
- DK
- Denmark
- Prior art keywords
- regions
- shiga toxin
- targeted binding
- selectively kill
- cytotoxic proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777130P | 2013-03-12 | 2013-03-12 | |
| PCT/US2014/023231 WO2014164693A2 (en) | 2013-03-12 | 2014-03-11 | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970487T3 true DK2970487T3 (da) | 2020-05-11 |
Family
ID=50625074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14726015.2T DK2970487T3 (da) | 2013-03-12 | 2014-03-11 | Cytotoksiske proteiner omfattende celle-målrettede bindingsregioner og Shiga toksin A-underenhedsregioner til selektivt at dræbe specifikke celletyper |
Country Status (21)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102037119B (zh) | 2008-05-23 | 2015-06-24 | Siwa有限公司 | 促进再生的方法、组合物及设备 |
| CN111363047A (zh) | 2013-03-12 | 2020-07-03 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| ES2749862T3 (es) | 2014-01-27 | 2020-03-24 | Molecular Templates Inc | Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos |
| US20210138076A2 (en) * | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| JP6814634B2 (ja) * | 2014-02-05 | 2021-01-20 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法 |
| ES2864124T3 (es) | 2014-03-11 | 2021-10-13 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| PT3604333T (pt) * | 2014-03-11 | 2021-06-07 | Molecular Templates Inc | Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| US20150328263A1 (en) | 2014-05-14 | 2015-11-19 | University Of Maryland, Baltimore | Cardiac stem cells for cardiac repair |
| KR102496206B1 (ko) | 2014-06-11 | 2023-02-06 | 몰레큘러 템플레이츠, 인코퍼레이션. | 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자 |
| AU2015318036B2 (en) | 2014-09-19 | 2021-07-01 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| US10387178B2 (en) * | 2014-10-29 | 2019-08-20 | Red Hat Israel, Ltd. | Idle based latency reduction for coalesced interrupts |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| WO2016126950A1 (en) * | 2015-02-05 | 2016-08-11 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| CN114656573B (zh) | 2015-05-30 | 2024-09-27 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| MX2018001208A (es) * | 2015-07-26 | 2018-03-26 | Molecular Templates Inc | Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+. |
| IL283726B2 (en) | 2016-02-19 | 2025-05-01 | Siwa Corp | A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| EP3443007A1 (en) | 2016-04-15 | 2019-02-20 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| AU2017340387A1 (en) * | 2016-10-04 | 2019-05-02 | University Of Florida Research Foundation, Inc. | Targeted effector proteins and uses thereof |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| US20190365806A1 (en) * | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| MX2019006656A (es) | 2016-12-07 | 2019-09-09 | Molecular Templates Inc | Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio. |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| KR102590672B1 (ko) | 2017-01-25 | 2023-10-18 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자 |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| BR112019021471A2 (pt) | 2017-04-13 | 2020-05-12 | Siwa Corporation | Anticorpo monoclonal humanizado de produto final da glicação avançada |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| WO2020084305A1 (en) * | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| US11713347B2 (en) | 2019-01-23 | 2023-08-01 | Millennium Pharmaceuticals, Inc. | CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors |
| US11414496B2 (en) | 2019-01-23 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Anti-CD38 binding domains |
| WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| KR102398485B1 (ko) | 2019-02-18 | 2022-05-16 | 에이티비 테라퓨틱스 | 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ,インコーポレイテッド | 治療用インターフェロンアルファ1タンパク質 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| US20210155671A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| EP4192874A1 (en) | 2020-08-05 | 2023-06-14 | Dragonfly Therapeutics, Inc. | Antibodies targeting egfr and use thereof |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| JP7707821B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707824B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707822B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707834B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707835B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707833B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707829B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707826B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707820B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707827B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707828B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707836B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707830B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707832B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707831B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| JP7707825B2 (ja) * | 2021-10-06 | 2025-07-15 | 株式会社三洋物産 | 遊技機 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| AU657087B2 (en) | 1989-12-22 | 1995-03-02 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5621083A (en) | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| AU6912294A (en) | 1993-05-12 | 1994-12-12 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| CA2265887A1 (en) | 1996-09-10 | 1998-03-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| CA2222993A1 (en) | 1998-02-04 | 1999-08-04 | The Ontario Cancer Institute | A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| WO2000004926A2 (en) | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US20010031485A1 (en) | 2000-03-22 | 2001-10-18 | Sibtech, Inc. | Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments |
| US7267973B2 (en) | 2000-03-22 | 2007-09-11 | Sibtech, Inc. | Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| WO2003066854A1 (fr) | 2002-02-04 | 2003-08-14 | Yoshida, Hideo | Agent anticancereux utilisant des variantes de verotoxines |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| WO2004058158A2 (en) | 2002-12-20 | 2004-07-15 | The Johns Hopkins University | Treatment of metastatic cancer with the b-subunit of shiga toxin |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| ATE467641T1 (de) | 2004-03-26 | 2010-05-15 | Molecular Templates Inc | Bibliothek von toxin mutanten und deren verwendung |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| JP2008543839A (ja) * | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| WO2007014238A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Single dose use of cd20-specific binding molecules |
| CA2664549A1 (en) | 2005-09-26 | 2007-03-29 | University Health Network | Library from toxin mutants, and methods of using same |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| JP4954293B2 (ja) | 2006-12-29 | 2012-06-13 | オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド | 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用 |
| FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
| DK2197903T3 (en) | 2007-09-04 | 2015-01-05 | Us Gov Health & Human Serv | Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY |
| US20090148904A1 (en) | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| CN102159243B (zh) | 2008-07-21 | 2015-08-19 | 免疫医疗公司 | 用于改良的治疗特征的抗体的结构变体 |
| US8969529B2 (en) | 2009-01-23 | 2015-03-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
| EP2456470A1 (en) | 2009-07-22 | 2012-05-30 | Cenix Bioscience GmbH | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| PL219845B1 (pl) | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| WO2012101235A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| SG191977A1 (en) * | 2011-02-01 | 2013-08-30 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
| US8895006B2 (en) | 2011-03-04 | 2014-11-25 | Rutgers, The State University Of New Jersey | Ricin ribosome binding protein compositions and methods of use thereof |
| EP2704739B1 (en) | 2011-05-06 | 2017-07-12 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Recombinant immunotoxin targeting mesothelin |
| PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| DE102012024450A1 (de) * | 2012-12-13 | 2014-06-18 | Maschinenfabrik Niehoff Gmbh & Co. Kg | Wickelspule für ein Gebinde, sowie Verfahren zu dessen Herstellung und Abwicklung |
| CN111363047A (zh) * | 2013-03-12 | 2020-07-03 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| ES2749862T3 (es) | 2014-01-27 | 2020-03-24 | Molecular Templates Inc | Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos |
| JP6814634B2 (ja) | 2014-02-05 | 2021-01-20 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法 |
| ES2864124T3 (es) | 2014-03-11 | 2021-10-13 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| PT3604333T (pt) | 2014-03-11 | 2021-06-07 | Molecular Templates Inc | Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| CN114656573B (zh) * | 2015-05-30 | 2024-09-27 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
-
2014
- 2014-03-11 CN CN202010215621.7A patent/CN111363047A/zh active Pending
- 2014-03-11 EP EP20155659.4A patent/EP3683240A1/en not_active Withdrawn
- 2014-03-11 US US14/774,130 patent/US20160068577A1/en not_active Abandoned
- 2014-03-11 ES ES14720298T patent/ES2808726T3/es active Active
- 2014-03-11 CA CA2902324A patent/CA2902324A1/en active Pending
- 2014-03-11 ES ES14726015T patent/ES2800630T3/es active Active
- 2014-03-11 HU HUE14726015A patent/HUE049470T2/hu unknown
- 2014-03-11 AU AU2014249107A patent/AU2014249107C1/en not_active Ceased
- 2014-03-11 SI SI201431553T patent/SI2970487T1/sl unknown
- 2014-03-11 DK DK14726015.2T patent/DK2970487T3/da active
- 2014-03-11 SM SM20200266T patent/SMT202000266T1/it unknown
- 2014-03-11 JP JP2016501176A patent/JP6548630B2/ja not_active Expired - Fee Related
- 2014-03-11 MX MX2015012808A patent/MX378807B/es unknown
- 2014-03-11 EP EP14720298.0A patent/EP2970478B1/en active Active
- 2014-03-11 JP JP2016501171A patent/JP6472784B2/ja not_active Expired - Fee Related
- 2014-03-11 EP EP20154062.2A patent/EP3666795A1/en not_active Withdrawn
- 2014-03-11 PT PT147260152T patent/PT2970487T/pt unknown
- 2014-03-11 PL PL14726015T patent/PL2970487T3/pl unknown
- 2014-03-11 KR KR1020157023206A patent/KR101990341B1/ko not_active Expired - Fee Related
- 2014-03-11 KR KR1020197016790A patent/KR102110127B1/ko not_active Expired - Fee Related
- 2014-03-11 LT LTEP14726015.2T patent/LT2970487T/lt unknown
- 2014-03-11 RS RS20200451A patent/RS60280B1/sr unknown
- 2014-03-11 CN CN201480013350.XA patent/CN105051067B/zh not_active Expired - Fee Related
- 2014-03-11 EP EP14726015.2A patent/EP2970487B1/en active Active
- 2014-03-11 US US14/774,609 patent/US10450354B2/en active Active
- 2014-03-11 WO PCT/US2014/023198 patent/WO2014164680A1/en not_active Ceased
- 2014-03-11 CA CA2902432A patent/CA2902432A1/en not_active Abandoned
- 2014-03-11 HR HRP20200553TT patent/HRP20200553T1/hr unknown
- 2014-03-11 WO PCT/US2014/023231 patent/WO2014164693A2/en not_active Ceased
-
2015
- 2015-08-09 IL IL240433A patent/IL240433B/en active IP Right Grant
-
2018
- 2018-02-20 US US15/899,428 patent/US20180258144A1/en not_active Abandoned
-
2019
- 2019-01-23 JP JP2019009370A patent/JP6745923B2/ja not_active Expired - Fee Related
- 2019-06-25 JP JP2019117230A patent/JP6896021B2/ja not_active Expired - Fee Related
- 2019-09-12 US US16/568,638 patent/US20200002387A1/en not_active Abandoned
- 2019-11-18 IL IL270745A patent/IL270745B/en active IP Right Grant
-
2020
- 2020-05-19 CY CY20201100456T patent/CY1123138T1/el unknown
- 2020-08-04 JP JP2020132606A patent/JP2020193205A/ja active Pending
-
2021
- 2021-06-08 JP JP2021095748A patent/JP2021164456A/ja active Pending
- 2021-06-14 IL IL283969A patent/IL283969B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202000266T1 (it) | Proteine citotossiche comprendenti regioni di legame per l'indirizzamento cellulare e regioni di subunita'a di tossina shiga per l'uccisione selettiva di specifici tipi di cellule | |
| IL272522A (en) | Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides | |
| PT3604333T (pt) | Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38 | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK3327027T3 (da) | Cytotoksiske peptider og antistof-medikamentkonjugater deraf | |
| DK3354661T3 (da) | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf | |
| DK3334500T3 (da) | Multiligand-lægemiddelskonjugater og anvendelser deraf | |
| DK2968552T3 (da) | Targeteringsmiddel-antistofkonjugater og anvendelser deraf | |
| DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
| DK3303373T3 (da) | Deimmuniserede Shiga toksin A-underenhedsstilladser og cellemålrettede molekyler omfattende samme | |
| IL245300A0 (en) | Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming | |
| DK2958944T3 (da) | Anti-dll3-antistof-pbd-konjugater og anvendelser deraf | |
| ZA201505813B (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| DK3102244T3 (da) | Antistoflægemiddelkonjugater og immuntoksiner | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3019533T3 (da) | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf | |
| DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK2812356T3 (da) | CDIM-bindende proteiner og anvendelser deraf | |
| IL230469A0 (en) | Curable compositions and membranes | |
| DK3354665T5 (da) | Modificerede alginater til celleindkapsling og celleterapi | |
| DK2996674T3 (da) | Farmaceutisk sammensætning omfattende et botulinum-neurotoxin og anvendelser deraf | |
| DK2953971T5 (da) | Il-11r-bindende proteiner og anvendelser deraf | |
| EP2912240A4 (en) | RINNE, RINNING ARRANGEMENT AND COMPONENTS THEREFOR | |
| DK2683643T3 (da) | Prostatacancercellelinjer, gensignaturer og anvendelser deraf | |
| DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf |